EMEA-002335-PIP01-18

Key facts

Active substance
Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3- zeta chimeric antigen receptor
Therapeutic area
Oncology
Decision number
P/0232/2018
PIP number
EMEA-002335-PIP01-18
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Treatment of mantle cell lymphoma
Route(s) of administration
Intravenous use
Contact for public enquiries
Kite Pharma EU B.V.

Tel. +1 4242091332
E-mail: regulatory@kitepharma.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating